Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network

Insulin-like growth factor-binding protein 2 (IGFBP2) is increasingly recognized as a glioma oncogene, emerging as a target for therapeutic intervention. In this study, we used an integrative approach to characterizing the IGFBP2 network, combining transcriptional profiling of human glioma with validation in glial cells and the replication-competent ASLV long terminal repeat with a splice acceptor/tv-a glioma mouse system. We demonstrated that IGFBP2 expression is closely linked to genes in the integrin and integrin-linked kinase (ILK) pathways and that these genes are associated with prognosis. We further showed that IGFBP2 activates integrin β1 and downstream invasion pathways, requires ILK to induce cell motility, and activates NF-κB. Most significantly, the IGFBP2/integrin/ILK/NF-κB network functions as a physiologically active signaling pathway in vivo by driving glioma progression; interfering with any point in the pathway markedly inhibits progression. The results of this study reveal a signaling pathway that is both targetable and highly relevant to improving the survival of glioma patients.

[1]  G. Li,et al.  Integrin-linked kinase regulates melanoma angiogenesis by activating NF-κB/interleukin-6 signaling pathway , 2011, Oncogene.

[2]  G. Fuller,et al.  Oncogene interactions are required for glioma development and progression as revealed by a tissue specific transgenic mouse model , 2011, Chinese journal of cancer.

[3]  Wei Zhang,et al.  Mouse models for cancer research , 2011, Chinese journal of cancer.

[4]  P. Defilippi,et al.  Integrin signalling adaptors: not only figurants in the cancer story , 2010, Nature Reviews Cancer.

[5]  Marian Brennan,et al.  Integrins as therapeutic targets: lessons and opportunities , 2010, Nature Reviews Drug Discovery.

[6]  G. Fuller,et al.  IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas , 2009, Proceedings of the National Academy of Sciences.

[7]  K. Gelmon,et al.  QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model , 2009, Breast Cancer Research.

[8]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[9]  M. Karin,et al.  Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. , 2009 .

[10]  K. Aldape,et al.  Aberrant NF-kappaB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factor. , 2008, International journal of oncology.

[11]  J. S. Rao,et al.  Blockade of Tumor Growth Due to Matrix Metalloproteinase-9 Inhibition Is Mediated by Sequential Activation of β1-Integrin, ERK, and NF-κB* , 2008, Journal of Biological Chemistry.

[12]  J. S. Rao,et al.  Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB. , 2008, The Journal of biological chemistry.

[13]  B. Bejcek,et al.  NF-kappaB controls growth of glioblastomas/astrocytomas. , 2008, Molecular and cellular biochemistry.

[14]  B. Bejcek,et al.  NF-κB controls growth of glioblastomas/astrocytomas , 2007, Molecular and Cellular Biochemistry.

[15]  G. Fuller,et al.  Insulin-like growth factor binding protein 2 promotes glioma development and progression , 2007, Proceedings of the National Academy of Sciences.

[16]  A. Hoeflich,et al.  IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. , 2006, Journal of molecular endocrinology.

[17]  G. Fuller,et al.  An Interaction between Insulin-like Growth Factor-binding Protein 2 (IGFBP2) and Integrin α5 Is Essential for IGFBP2-induced Cell Mobility* , 2006, Journal of Biological Chemistry.

[18]  S. Dedhar,et al.  Integrin-linked kinase: a cancer therapeutic target unique among its ILK , 2005, Nature Reviews Cancer.

[19]  G. Fuller,et al.  Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomas , 2004, Laboratory Investigation.

[20]  M. Elmlinger,et al.  Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. , 2004, Journal of molecular endocrinology.

[21]  S. Dedhar,et al.  Integrin-linked Kinase Regulates Inducible Nitric Oxide Synthase and Cyclooxygenase-2 Expression in an NF-κB-dependent Manner* , 2002, The Journal of Biological Chemistry.

[22]  G. Fuller,et al.  Insulin‐like Growth Factor Binding Protein 2: Gene Expression Microarrays and the Hypothesis‐generation Paradigm , 2002, Brain pathology.

[23]  D. Louis,et al.  PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.

[24]  O. Kallioniemi,et al.  Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. , 2000, Cancer research.

[25]  E. Holland.  A Mouse Model for Glioma: Biology, Pathology, and Therapeutic Opportunities , 2000, Toxicologic pathology.

[26]  W. Yung,et al.  Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. , 1999, Cancer research.

[27]  H. Varmus,et al.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. , 1998, Genes & development.

[28]  H. Varmus,et al.  Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Elmlinger,et al.  Functional role of insulin-like growth factor binding proteins. , 1997, Hormone research.

[30]  C. Cabañas,et al.  Activated Conformations of Very Late Activation Integrins Detected by a Group of Antibodies (HUTS) Specific for a Novel Regulatory Region(355425) of the Common 1 Chain (*) , 1996, The Journal of Biological Chemistry.

[31]  S. Dedhar,et al.  Regulation of cell adhesion and anchorage-dependent growth by a new β1-integrin-linked protein kinase , 1996, Nature.

[32]  M. Humphries,et al.  Identification of a novel anti‐integrin monoclonal antibody that recognises a ligand‐induced binding site epitope on the β1 subunit , 1995, FEBS letters.